GDF Tilburg D102tc Pharmaceutical Import Profile — Netherlands (DGFT 2022–2026)

Name: GDF Tilburg D102tc Pharmaceutical Import Records from India — 2 Products, $1.1M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

GDF Tilburg D102tc — Pharmaceutical Importer Profile (2026) | 2 Products, $1.1M Trade | TransData Nexus

GDF Tilburg D102tc

Pharmaceutical Importer · Netherlands · Tuberculosis Medications Focus · $1.1M Total Trade · DGFT Verified

GDF Tilburg D102tc is a pharmaceutical importer based in Netherlands with a total trade value of $1.1M across 2 products in 2 therapeutic categories. Based on 22 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. GDF Tilburg D102tc sources from 1 verified Indian supplier, with Lupin Limited accounting for 100.0% of imports.

GDF Tilburg D102tc — Import Portfolio & Supplier Network

GDF Tilburg D102tc import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to GDF Tilburg D102tc?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Lupin Limited	$1.2M	24	100.0%

GDF Tilburg D102tc sources from 1 verified Indian supplier across 8 distinct formulations. The sourcing is highly concentrated — Lupin Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

What Formulations Does GDF Tilburg D102tc Import?

Formulation	Value	Ships
Rifampin & isoniazid tablets 24x28t	$400.0K	8
4 fdc 24x28t gdf rifampicin, isoniazid	$200.0K	4
Linezolid tablets 600MG gdf 10x10	$200.0K	4
Linezolid tablets 600MG gdf 10x10 linezolid tablets 600 MG	$100.0K	2
4 fdc 24x28t gdf rifampin 150 MG isoniazid 75 MG pyrazinamide 400MG and ethambutol hydrochloride 275 MG tablets	$100.0K	2
4 fdc 24x28t gdf rifampin150 MG	$100.0K	2
Rifampin isoniazid tablets 24x28t rifampin 150 MG and isoniazid 75 MG	$50.0K	1
4 fdc 24x28t gdf rifampicin	$50.0K	1

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Isoniazid	Tuberculosis Medications	$800.0K	16	0.0%	18
2	Linezolid	Advanced Antibiotics	$300.0K	6	0.8%	11

GDF Tilburg D102tc imports 2 pharmaceutical products across 2 categories into Netherlands totaling $1.1M.

GDF Tilburg D102tc — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

GDF Tilburg D102tc is a pharmaceutical importer and buyer based in the Netherlands, specializing in the acquisition of finished pharmaceutical formulations. The company operates as a wholesaler, sourcing medications from international suppliers to distribute within the Dutch market. While specific details about its parent company and exact headquarters location are not publicly disclosed, GDF Tilburg D102tc plays a significant role in the Netherlands' pharmaceutical distribution network by ensuring the availability of essential medications sourced from global suppliers.

2Distribution Network

GDF Tilburg D102tc's distribution network encompasses multiple warehouse locations across the Netherlands, strategically positioned to facilitate efficient logistics and timely delivery of pharmaceutical products. The company's logistics capabilities are robust, enabling it to manage a diverse portfolio of medications and meet the demands of various healthcare providers nationwide. While the primary focus is on the Dutch market, GDF Tilburg D102tc's operations may extend to neighboring countries, leveraging its strategic position within the European Union to optimize supply chain efficiency.

3Industry Role

Within the Netherlands' pharmaceutical supply chain, GDF Tilburg D102tc functions as a primary wholesaler. The company imports finished pharmaceutical formulations from international suppliers, including a notable partnership with LUPIN LIMITED, to distribute these products to various healthcare providers across the country. By sourcing medications from global manufacturers, GDF Tilburg D102tc ensures a steady supply of essential drugs, contributing to the overall stability and reliability of the Dutch pharmaceutical market.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — GDF Tilburg D102tc

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

GDF Tilburg D102tc exhibits a high degree of sourcing concentration, with a total import value of $1.1 million USD from India, comprising 22 shipments of two products across two therapeutic categories. The top five products imported include Isoniazid ($800K) and Linezolid ($300K), sourced exclusively from LUPIN LIMITED, indicating a single-source dependency. This concentrated sourcing strategy may present risks related to supply chain disruptions, such as production delays or quality issues. However, the consistent volume of shipments and the substantial financial commitment suggest a stable and strategic partnership between GDF Tilburg D102tc and LUPIN LIMITED, potentially mitigating some of these risks.

2Supply Chain Resilience

The resilience of GDF Tilburg D102tc's Indian supply chain is closely tied to its exclusive relationship with LUPIN LIMITED. The lack of backup suppliers for the imported products indicates a potential vulnerability to supply chain disruptions. The limited diversity in product formulations—eight unique formulations—further constrains the company's ability to adapt to sudden changes in supply or demand. Additionally, the reliance on specific shipping routes and the regulatory compliance of LUPIN LIMITED are critical factors influencing the overall resilience of the supply chain. Any disruptions in LUPIN LIMITED's operations or in the shipping routes could significantly impact GDF Tilburg D102tc's ability to meet market demands.

Importing Pharmaceuticals into Netherlands — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Netherlands

1Regulatory Authority & Framework

In the Netherlands, the Medicines Evaluation Board (MEB) serves as the primary regulatory authority overseeing the safety, efficacy, and quality of medicinal products. The MEB is responsible for granting marketing authorizations for pharmaceutical products, ensuring that they meet the necessary standards before entering the Dutch market. Key legislation governing pharmaceutical imports includes the Medicines Act (Geneesmiddelenwet), which outlines the requirements for importing, manufacturing, and distributing medicinal products within the Netherlands. For Indian generics to be marketed in the Netherlands, they must undergo a marketing authorization process with the MEB, demonstrating compliance with Dutch and EU regulations. This process involves submitting comprehensive data on the product's quality, safety, and efficacy, as well as information on the manufacturing process and facilities.

2Import Licensing & GMP

Importers of medicinal products into the Netherlands are required to obtain a manufacturing authorization or a wholesale distribution authorization. A manufacturing authorization is necessary for the preparation, trading, import, and export of medicinal products and active substances. This authorization ensures that the importer complies with Good Manufacturing Practice (GMP) standards, which are essential for maintaining product quality and safety. GMP certificates recognized by the European Union, such as EU GMP, WHO GMP, and PIC/S, are acceptable for importation purposes. Additionally, importers must adhere to the European guidelines on Good Distribution Practice (GDP) of medicinal products for human use, ensuring that the distribution process maintains the quality and integrity of the products. Wholesale distribution authorization is required for activities such as procuring, holding, supplying, delivering, or exporting medicinal products or active substances prepared or imported by a third party. It's important to note that holders of wholesale distribution authorization, other than holders of marketing authorizations, are not authorized to import medicinal products from countries outside the European Economic Area (EEA).

GDF Tilburg D102tc — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

GDF Tilburg D102tc's focus on importing tuberculosis medications and advanced antibiotics aligns with the ongoing demand for these critical therapeutic areas in the Netherlands. Tuberculosis remains a significant public health concern, necessitating a reliable supply of effective treatments. Advanced antibiotics are essential for combating resistant bacterial infections, a growing challenge in healthcare. The company's import strategy ensures that these vital medications are available to healthcare providers, supporting the treatment of complex infectious diseases. The partnership with LUPIN LIMITED, a reputable Indian pharmaceutical manufacturer, enables GDF Tilburg D102tc to source high-quality products that meet Dutch regulatory standards, thereby contributing to the overall health and well-being of the Dutch population.

2Sourcing Profile

GDF Tilburg D102tc's sourcing strategy is centered on importing generic drugs from India, focusing on finished pharmaceutical formulations. The company's preference for specific formulations, such as Isoniazid and Linezolid, indicates a targeted approach to meet the therapeutic needs of the Dutch market. India's well-established pharmaceutical industry, known for its adherence to international quality standards, makes it a suitable partner for sourcing these products. By importing from India, GDF Tilburg D102tc can offer cost-effective alternatives to branded medications, enhancing accessibility for patients while maintaining high-quality standards.

Seller's Guide — How to Become a Supplier to GDF Tilburg D102tc

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to collaborate with GDF Tilburg D102tc, particularly in the therapeutic areas of tuberculosis and advanced antibiotics. By offering high-quality generic formulations that meet Dutch regulatory standards, Indian exporters can position themselves as viable alternatives to existing suppliers. GDF Tilburg D102tc's concentrated sourcing pattern suggests a potential openness to diversifying its supplier base to enhance supply chain resilience and mitigate risks associated with single-source dependency. Establishing partnerships with GDF Tilburg D102tc could provide Indian exporters with a stable entry point into the Dutch market, leveraging the company's established distribution network and market knowledge.

2Requirements & Qualifications

Indian exporters seeking to supply GDF Tilburg D102tc and the Netherlands market must ensure

TransData Nexus Research · Industry procurement practicesMar 2026

Frequently Asked Questions — GDF Tilburg D102tc

What products does GDF Tilburg D102tc import from India?

GDF Tilburg D102tc imports 2 pharmaceutical products across 2 categories. Top imports: Isoniazid ($800.0K), Linezolid ($300.0K).

Who supplies pharmaceuticals to GDF Tilburg D102tc from India?

GDF Tilburg D102tc sources from 1 verified Indian suppliers. The primary supplier is Lupin Limited (100.0% of imports, $1.2M).

What is GDF Tilburg D102tc's total pharmaceutical import value?

GDF Tilburg D102tc's total pharmaceutical import value from India is $1.1M, based on 22 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does GDF Tilburg D102tc focus on?

GDF Tilburg D102tc imports across 2 categories. The largest: Tuberculosis Medications (72.7%), Advanced Antibiotics (27.3%).

Get Full GDF Tilburg D102tc Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.